Skip to main content

May 2016

 

 

academics

 

Clinical research courses

Opening for Executive - Medical Information- Pharma in Novartis

A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

Post: Executive - Medical Information

Job as Manager -Medical Writing in Hospira

Hospira is the world's leading provider of injectable drugs and infusion technologies. Through our broad, integrated portfolio, we are uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs.
Through our offering of high-quality, lower-cost generic medications, we continue to help reduce the overall costs of healthcare — to improve both the affordability of care for patients and the financial strength of the global healthcare system.

Working opportunity for Senior Manager Analytics in United Health Group

At United Health Group, their mission is to help people live healthier lives. To achieve this goal, they are focused on building a modern, adaptable, innovative and inclusive system of health care services.
Their scale and potential to improve health makes them one of the most visible stewards of America’s vast health care system. Entrusted with both important resources and responsibilities, they are involved on a daily basis in decision-making that has life-changing consequences for millions of Americans.

Job as Clinical distribution coordinator in Novartis

A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

Post: Clinical distribution coordinator

Vacancy for Pharmacist (92 posts) in Urban Primary Health Centres

Government of India has launched National Urban Health Mission as sub mission of National Health Mission during 2013-14 with an aim to improve the health status of the urban population in general, but particularly of the poor and other disadvantages sections, by facilitating equitable access to quality health care through a revamped public health system, partnerships, community based mechanism with the active involvement of the urban local bodies. All the Urban Local Bodies (ULBs) with more than 50000 population are covered under NUHM.

Post: Pharmacist-(92)

Vacancies for Pharmacists (30 posts) in Office of the CDMO

Applications in the prescribed proformed are invited from eligible candidates for selection and engagement of the following newly created posts under the Chief District Medical Officer, Jajpur to be filled on Contractual basis with monthly remuneration mentioned against each of the post. The application for the above posts should reach in the office of the C.D.M.O., At / Po / Dist - Jajpur, PIN-755001, through Speed Post / Regd. Post only on or before Dt.20.05.2016 by 05.00 P.M. The application received after due date shall not be considered under any circumstances and will be rejected. The candidate has to apply separate application for separate post.

Aurobindo Pharma Limited announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Zolmitriptan Tablets, 2.5 mg and 5 mg. This product is expected to be launched in Q2 FY16-17.

Caladrius Biosciences, Inc., announces that its product candidate CLBS03 (autologous expanded polyclonal regulatory T cells, or Tregs) for the treatment of recent-onset type 1 diabetes (“T1D”) was granted orphan-drug designation by the US Food and Drug Administration (“FDA”) for the treatment of type 1 diabetes mellitus with residual beta cell function.

H3 Biomedicine Inc., announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Investigational New Drug (IND) application to begin Phase 1 clinical trials for its lead oncology drug candidate H3B-8800. The compound is an oral and selective small molecule modulator of splicing factor 3b subunit 1 (SF3B1), which is being developed by H3 Biomedicine as an anticancer therapeutic agent for the potential treatment of select hematologic malignancies.